Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 10/20 | 0.70 |
| ▸ | RAB9A | P51151 | 10/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.70 |
| ▸ | NOTUM | Q6P988 | 4/20 | 0.57 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 7/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.55 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.55 |
| ▸ | RELA | Q04206 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL46426 | 0.83 | NPC1 (1.00) | NPC1RAB9ASMN1; SMN2NOTUMATAD2 | |
| SCHEMBL10969002 | 0.81 | NPC1 (0.61) | NPC1RAB9ASMN1; SMN2NOTUMATAD2 | |
| SCHEMBL28859116 | 0.81 | NPC1 (0.61) | NPC1RAB9ASMN1; SMN2NOTUMATAD2 | |
| SCHEMBL4343181 | 0.80 | NPC1 (0.94) | NPC1RAB9ASMN1; SMN2NOTUMATAD2 | |
| Neovadrine SCHEMBL22799863 | 0.80 | PKM (0.71) | NPC1RAB9ASMN1; SMN2ATAD2HPGD | |
| SCHEMBL6737766 | 0.80 | NPC1 (0.74) | NPC1RAB9ASMN1; SMN2NOTUMATAD2 | |
| SCHEMBL22996209 | 0.78 | KDM4E (0.66) | NPC1RAB9ASMN1; SMN2HPGDPOLB | |
| SCHEMBL21777005 | 0.78 | RAB9A (0.60) | NPC1RAB9ASMN1; SMN2NOTUMHPGD | |
| SCHEMBL23451582 | 0.78 | NPC1 (0.72) | NPC1RAB9ASMN1; SMN2NOTUMPOLB | |
| SCHEMBL5638673 | 0.78 | NPC1 (0.71) | NPC1RAB9ASMN1; SMN2NOTUMATAD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4618979-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | Tenvie Therapeutics Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| EP-4558494-A1 | 1,3,4-OXADIAZOLE DERIVATIVES AS SELECTIVE HISTONE DEACETYLASE 6 INHIBITORS | ITALFARMACO S.p.A. (IT) | 2025-05-28 | — | — | EP | disclosed |
| CN-119562949-A | 1,3, 4-Oxadiazole derivatives as selective histone deacetylase 6 inhibitors | 意大发马克股份公司 | 2025-03-04 | — | — | CN | disclosed |
| WO-2024108155-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| WO-2024017897-A1 | 1,3,4-OXADIAZOLE DERIVATIVES AS SELECTIVE HISTONE DEACETYLASE 6 INHIBITORS | ITALFARMACO S.P.A. (IT) | 2024-01-25 | — | — | WO | disclosed |
| WO-2024017897-A1 | 1,3,4-OXADIAZOLE DERIVATIVES AS SELECTIVE HISTONE DEACETYLASE 6 INHIBITORS | ITALFARMACO S.P.A. (IT) | 2024-01-25 | — | — | WO | disclosed |
| US-11634391-B2 | Compounds which are inhibitors of Notum | UCL BUSINESS LTD (GB) | 2023-04-25 | — | — | US | disclosed |
| EP-3843844-A1 | COMPOUNDS | UCL Business Ltd (GB) | 2021-07-07 | — | — | EP | disclosed |
| US-20210171475-A1 | COMPOUNDS | UCL BUSINESS LTD (GB) | 2021-06-10 | — | — | US | disclosed |
| US-20210171475-A1 | COMPOUNDS | UCL BUSINESS LTD (GB) | 2021-06-10 | — | — | US | disclosed |
| US-9150561-B2 | Thiazole derivatives and use thereof | MERCK SERONO S.A. (CH) | 2015-10-06 | — | — | US | disclosed |
| US-20150150836-A1 | METHODS TO TREAT DYSREGULATED BLOOD GLUCOSE DISORDERS | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2015-06-04 | — | — | US | disclosed |
| US-20140228365-A1 | THIAZOLE DERIVATIVES AND USE THEREOF | MERCK SERONO S.A. (CH) | 2014-08-14 | — | — | US | disclosed |
| US-8802861-B2 | Thiazole derivatives and use thereof | MERCK SERONO SA (CH) | 2014-08-12 | — | — | US | disclosed |
| CN-1926121-B | Thiazole derivatives and uses thereof | MERCK SERONO SA | 2012-06-13 | — | — | CN | disclosed |
| US-20090029998-A1 | Thiazole Derivatives and Use Thereof | APPLIED RESEARCH SYSTEM ARS HOLDING N.V. (NL) | 2009-01-29 | — | — | US | disclosed |
| EP-1709019-B1 | THIAZOLE DERIVATIVES AND USE THEREOF | APPLIED RESEARCH SYSTEMS (AN) | 2007-08-08 | — | — | EP | disclosed |
| CN-1926121-A | Thiazole derivatives and uses thereof | APPLIED RESEARCH SYSTEMS (AN) | 2007-03-07 | — | — | CN | disclosed |
| EP-1709019-A2 | THIAZOLE DERIVATIVES AND USE THEREOF | Applied Research Systems ARS Holding N.V. (AN) | 2006-10-11 | — | — | EP | disclosed |
| WO-2005068444-A2 | THIAZOLE DERIVATIVES AND USE THEREOF | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2005-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140228365-A1 | THIAZOLE DERIVATIVES AND USE THEREOF | PF4, TEC, PDGFRB | NPC1 3795/4885RAB9A 2095/4885SMN1; SMN2 4287/4885 |
| US-11634391-B2 | Compounds which are inhibitors of Notum | NOTUM, GOT2, GOT1 | NPC1 51/4885RAB9A 2177/4885SMN1; SMN2 451/4885 |
| US-20210171475-A1 | COMPOUNDS | GOT2, GOT1, OAT | NPC1 7/4885RAB9A 1162/4885SMN1; SMN2 74/4885 |
| US-20090029998-A1 | Thiazole Derivatives and Use Thereof | PDGFRB, PDGFRA, TEC | NPC1 3530/4885RAB9A 3033/4885SMN1; SMN2 1799/4885 |
| US-20150150836-A1 | METHODS TO TREAT DYSREGULATED BLOOD GLUCOSE DISORDERS | SLC2A4, SLC2A2, SLC2A3 | NPC1 467/4885RAB9A 2195/4885SMN1; SMN2 1534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.